Page 1588 - Small Animal Internal Medicine, 6th Edition

1560 Index

Heart failure (Continued) Heartworm disease (Continued) Hematemesis (Continued) Hemostatic defects
chronic Dirofilaria immitis diagnostic approach to, 400f buccal mucosa bleeding time test for,
amlodipine for, 71 life cycle of, 193 gastroduodenal ulceration and erosion clinical manifestations of, 1388–1389,
1391–1392, 1391b
VetBooks.ir benazepril for, 68 in dogs 195–196 Hematochezia, 402, 402b clinicopathologic evaluation of,
angiotensin-converting enzyme
as cause of, 397–398
microfilaria identification tests,
1388b, 1391f
inhibitors for, 67–68
Hematocrit, 1340
1389–1393, 1390f
captopril for, 64t, 68
client education about, 73–74 adulticides, 199b, 200–201 Hematologic system disseminated intravascular
antigen tests for, 195
chemotherapy complications of,
dietary considerations for, 72–73 caval syndrome secondary to, 1276–1280 coagulation. see Disseminated
digoxin for, 69–70 202–203 monitoring of, during chemotherapy, intravascular coagulation
drug therapy for, 64t clinical features of, 196–197 1279 mixed (combined), 1400–1404
enalapril for, 68 clinicopathologic findings, 197–201 Hematopoietic tissue, 1259 overview of, 1387
furosemide for, 64t, 66 diagnosis of, 197 Hematuria, 650–652, 650f–651f, 651b, point-of-care tests for, 1389, 1389t
general considerations for, 66 echocardiographic findings, 197, 664, 666, 666b primary
hydralazine for, 71 197f Hemi-inattention syndrome, 1043, description of, 1388b, 1389
hyponatremia in, 74 electrocardiographic findings, 197 1074 platelet dysfunction, 1397–1399,
loop diuretics for, 66–67 heart sounds associated with, 196 Hemiparesis, 1045t 1397b
monitoring of, 73–74, 74b ivermectin prophylaxis, 198 Hemiplegia, 1045t von Willebrand disease, 1398–1399,
nitrates for, 71–72 management protocol for, 199b Hemoglobin 1398t
pimobendan for, 69 melarsomine dihydrochloride for, complete blood count assessment of, screening tests for, 1392t
prazosin for, 71 199, 199b 318 secondary, 1399–1400
reevaluations, 73–74 microfilaria identification tests, oxygen saturation of, 318 congenital clotting factor
refractory, 74–75 195–196, 195t Hemolysis deficiencies, 1399–1400
salt restriction for, 72 microfilaricide therapy, 207–208 extravascular, 1231 description of, 1388b, 1389
spironolactone for, 67 pathophysiology of, 194–195 peracute, 1354 evaluation of, 1399
thiazide diuretics for, 67 physical examination of, 196 prevention of, 1235–1237 vitamin K deficiency, 1400
cough and, 3, 282 preadulticide evaluation, 197–199 Hemolytic anemia thrombocytopenia. see
definition of, 55 prevention of, 198, 203–207 causes of, 1347t Thrombocytopenia
diastolic dysfunction as cause of, 65 pulmonary arterial disease congenital, 1348 thrombosis, 1405, 1405f
diuresis for, 61 associated with, 201 corticosteroids for, 1349 Hemostatic plugs, 1401
diuretics for, 66–67 pulmonary complications, 201 description of, 843–844, 930, Hemothorax, 382
drug therapy, 61–65 pulmonary thromboembolic 1346–1351, 1348f Heparin
exercise capacity reductions secondary complications, 201–203 diagnosis of, 1248t arterial thromboembolism in cats
to, 58 radiographic findings, 196 immune-mediated treated with, 227b, 228
exercise intolerance and, 1 renal amyloidosis, 194 blood smear findings, 1234f disseminated intravascular coagulation
follow-up for, 65–66 right-sided congestive heart failure blood transfusion for, 1237 treated with, 1403
inotropic support for, 63–65 secondary to, 202–203 bone marrow evaluation in, 1235 immune-mediated diseases treated
management of, 55–76 serologic tests for, 195 clinical features of, 1232 with, 1255t–1256t
monitoring of, 65–66 severity classifications, 196t cytologic findings, 1232f low-molecular-weight
neurohormonal responses to, 56–58, treatment of, 197–199 definition of, 1231 arterial thromboembolism uses of,
57f villous proliferations associated description of, 1348f, 1349–1351, 228, 230
New York Heart Association with, 194 1350f dosage of, 229
classification scheme for, 59–60 echocardiographic findings, 197, 197f, diagnosis of, 1215–1216, 1232–1235 pregnancy thrombosis treated with,
other respiratory signs of, 3 206 dog breeds at risk for, 1232b 967
pressure overload associated with, 59t electrocardiographic findings, 197, etiology of, 1231 monitoring of, 228
renal effects of, 58 206–207 genetic predisposition of, 1231 unfractionated, 228
severity of, 59–60, 60t geographic distribution of, 193 glucocorticoids for, 1235–1236 Hepatic amyloidosis, 575–576
signs of, 1–3, 2b idiopathic feline bronchitis versus, hemolysis prevention in, 1235–1237 Hepatic biopsy. see Liver biopsy
supplemental oxygen for, 61 329t history-taking, 1233b Hepatic congestion, 617
syncope and, 1–3 microfilaria infectious diseases that cause, 1232b Hepatic cystadenoma, 575f
systemic responses to, 56–58 tests for identifying, 195–196, 195t laboratory tests, 1232–1233, 1233b, Hepatic encephalopathy, 522–524,
treatment of, 61–66, 129 treatment for, 200 1234f, 1234t 522f–523f, 523b
vasodilation for, 61–63, 64t pulmonary arteries, endothelial injury, myelofibrosis in, 1235 clinical signs of, 524, 524f, 524b
volume-flow overload associated with, 222 nonregenerative, 1239t management of, 606–608, 607b, 609b
59t pulmonary hypertension caused by, physical examination of, 1233b acute, 606f, 608–609, 609b
weakness and, 1 193, 287 prednisone for, 1350 pathogenesis of, 522–524, 522f–523f
Heart rate variability, 48 radiographic findings, 196, 205f, 206 prognosis for, 1237–1238 precipitating factors for, 523b
Heart rhythm, 37 serologic tests for, 195 regenerative, 1239t treatment of, 1440t
Heart sounds severity of, 196t secondary, 1231, 1234, 1235t Hepatic lipidosis
auscultation of, 7–8 Wolbachia pipientis, 193 spherocytes in, 1233, 1234t feline, 561–567
in cardiac tamponade, 177–178 Heat cycle supportive care for, 1237 primary, 561
classification of, 7 silent, 953 thromboembolism prevention in, secondary, 561–567
first, 5, 8 split, 953–954 1237 Hepatitis
fourth, 9 Heinz bodies, 1345t thrombosis associated with, acute, 598–599, 598b
gallop sounds as, 9 Helicobacter spp., 1533t–1535t, 1539 223 chronic. see Chronic hepatitis, canine
in heartworm disease in dogs, 196 antibiotics for, 1440t treatment of, 1235–1237 Hepatobiliary disease, 518–530
second, 8 chronic gastritis caused by, 463 vaccinations and, 1231 abdominal pain in, 519
third, 9 gastritis caused by, 443 nonspherocytic, 1347t bilirubinuria and, 525–527, 526f–527f
transient, 7–9 H. pylori, 464, 464f spherocytic, 1396 in cats, 561–583
Heartguard. see Ivermectin Hemangiomas, 1413–1414 Hemophilia A, 1399 biliary tract diseases. see Feline
Heartworm disease, 190–210 Hemangiosarcoma Hemophilia B, 1399 biliary tract disease
in cats abdominal, 513 Hemoplasmas, 1432–1433 characteristics of, 563t
adulticide therapy for, 206 canine, 1323f Hemoptysis, 282 clinical features of, 562
antibody tests for, 206 clinical features of, 1322 Hemorrhagic cystitis, 1284 diagnosis of, 562–565, 564f
antigen tests for, 205–206 clinicopathologic features of, 1322 Hemorrhagic effusions extrahepatic bile duct obstruction,
clinical features of, 204–206 description of, 176, 178, 185, 1322, pericardial, 176–177, 182–183 573–574, 573b
description of, 203 1413 pleural, 361t, 362f, 363–364 general considerations for, 561
diagnosis of, 204–206 diagnosis of, 1323 Hemorrhagic gastroenteritis, 462–463, hepatic amyloidosis, 575–576
echocardiographic findings, 206 fine-needle aspiration of, 1323 1368 hepatic lipidosis, 561–567
electrocardiographic findings, intraabdominal, 1323f Hemostasis hepatobiliary manifestations, of
206–207 primary splenic, 1325f cage-side tests for, 1390 systemic disease, 582
pathophysiology of, 204–206 prognosis for, 1324–1325 disorders of, 1387–1406 neoplasia, 576–577
radiographic findings, 205f, 206 treatment of, 1324–1325, 1324f in Greyhounds, 1361, 1366t prognosis for, 565–567
serologic tests for, 205 Hematemesis, 396f, 397–398 laboratory evaluation of, 1392, 1392t treatment of, 565–567, 565f,
surgical treatment of, 207 acute vomiting without, 394–395 physiology of, 1387–1388 566b–567b
treatment of, 207 causes of, 397b point-of-care tests for, 1389, 1389t types of, 562t